Search Login Register
Thalidomide
(Thalomid)
Summary
Description:
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
Also Known As:
Thalomid; Celgene Brand of Thalidomide; Sedoval; 1H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-
Networked: 3480
relevant articles (542 outcomes,
683 trials/studies)
for this Drug
Key Diseases for which Thalidomide is
Relevant
-
Multiple Myeloma
:
191 outcomes 201 studies in 1014 results
-
Neoplasms (Cancer)
:
39 outcomes 65 studies in 383 results
-
Crohn Disease (Crohn's Disease)
:
22 outcomes 16 studies in 83 results
-
Erythema Nodosum
:
22 outcomes 10 studies in 125 results
-
Leprosy (Hansen's Disease)
:
16 outcomes 9 studies in 128 results
Show All >>
Drugs Related to Thalidomide
-
bortezomib (Velcade)
-
lenalidomide (CC 5013)
-
Dexamethasone (Maxidex)
-
Cyclophosphamide (Cytoxan)
-
Melphalan (Alkeran)
-
Prednisone (Sone)
-
Proteasome Endopeptidase Complex (Proteasome)
-
Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
-
Adrenal Cortex Hormones (Corticosteroids)
-
Prednisolone (Predate)
Show All >>
Therapies Related to Thalidomide
-
Drug Therapy (Chemotherapy)
-
Stem Cell Transplantation
-
Bone Marrow Transplantation (Transplantation, Bone Marrow)
-
Radiotherapy
-
Aftercare (After-Treatment)
Show All >>
CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.